Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the best dose of sonidegib when given together with pembrolizumab
and to see how well they work in treating patients with solid tumor that has spread to other
places in the body (advanced). Sonidegib may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving sonidegib and pembrolizumab may work
better than standard treatment in treating patients with advanced solid tumors.